Assessing the Role of Potential Biomarkers in Antimony Susceptible and Resistant Clinical Isolates of L. donovani from India by Maharjan, Mahendra et al.
Nepal Journal of Biotechnology. Dec .  2016  Vol. 4, No. 1: 1-13   ISSN 2091-1130(Print)/ISSN 2467-9319 (online) 
 
ORIGINAL RESEARCH ARTICLE 
©NJB, Biotechnology Society of Nepal    1     Nepjol.info/index.php/njb
         
Assessing the Role of Potential Biomarkers in Antimony 
Susceptible and Resistant Clinical Isolates of L. donovani from 
India  
Mahendra Maharjan1,2*, Swati Mandal1, Rentala Madhubala1 
1School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India. 
2 Central Department of Zoology, Tribhuvan University, Kathmandu, Nepal. 
 
Abstract 
Failure of antimonial drugs, the mainstay therapy for leishmaniasis has become an escalating 
problem in the treatment of Indian leishmaniasis. Using 14 clinical isolates from both visceral 
(VL) and post-kala-azar dermal leismaniasis (PKDL) patients, we have examined the role of 
ATP-binding cassette transporter (ABC transporter) gene, multidrug resistant protein A 
(MRPA) and two building blocks of the major thiol, trypanothione namely, ornithine 
decarboxylase gene (ODC) (a rate limiting enzyme in the polyamine biosynthesis) and γ- 
glutamylcysteine synthetase (γ-GCS) (a rate limiting enzyme in glutathione biosynthesis) in 
antimony resistance. Amplification of these three genes was observed in some but not all 
clinical isolates. Increased expression of the three RNAs as determined by real-time PCR was 
observed in all SAG-R clinical isolates. Significant increase in cysteine and glutathione levels 
was observed in the resistant isolates. Our studies report the underlying mechanism of 
antimony resistance in the clinical isolates. 
Key words: ABC transporter, ornithine decarboxylase, γ- glutamylcysteine synthetase, 
antimony resistance. 
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Introduction 
The protozoan parasite Leishmania is the 
causative agent of kala-azar and is responsible 
for a variety of clinical manifestations. It causes a 
wide spectrum of diseases ranging from the 
simple self healing cutaneous form to the 
debilitating visceral form. Visceral leishmaniasis 
(VL) is caused by L. donovani in the Indian sub-
continent. Pentavalent antimonials (SbV) are the 
first line of drug used in the treatment against all 
forms of leishmanial infections [1,2]. Resistance 
to this drug is becoming a major barrier in the 
treatment of VL in many endemic regions 
particularly in India [3]. Kala-azar transmission 
in India is thought to be anthroponotic and post-
kala-azar dermal leismaniasis (PKDL) patients 
are considered to serve as a source for new 
outbreaks [4]. The post-kala-azar dermal 
leismaniasis (PKDL) is a sequel to VL in India 
and Sudan; the disease develops months to years 
after the patient’s recovery from VL [5]. 
The mechanism of action of sodium antimony 
gluconate (SAG) remained an enigma for more 
than 60 years of its effective use against all forms 
of leishmaniasis. It is generally agreed that 
pentavalent form (SbV) is reduced to a more 
toxic trivalent form (SbIII) which constitutes the 
active form of the drug against the parasite [6]. 
Molecules possibly implicated in reduction of 
SbV to SbIII include host and parasite thiols and 
two newly discovered parasite enzymes thiol-
dependent reductase (TDR1) and arsenate 
reductase (ACR2) [7-9]. A loss of drug activation 
is reported to lead to resistance [10]. The route of 
entry of SbV into Leishmania cells is still 
unknown but SbIII has been reported to be 
transported in Leishmania through 
aquaglyceroporin (AQP1) [11,12]. Recent 
evidence has suggested that part of the mode of 
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action of SbV could be in depleting the cells of its 
reduced thiols [13]. Trypanothione (TSH), a 
major reduced thiol of Leishmania is a N1, N8 
bisglutathione spermidine conjugate. It is 
thought to bind to the active reduced form of the 
metal. These metal-trypanothione conjugates are 
either sequestered into an intracellular organelle 
by the ABC transporter MRPA or extruded 
outside the cell by an efflux pump [13-16]. A 
number of candidate genes associated with 
increased thiol concentration have been 
described in Leishmania laboratory mutants.  
Resistance was induced in these mutants in vitro 
in the presence of antimony related metals such 
as arsenic or antimony [2,17,18].  
However, till date it remains unclear as to 
whether similar mechanisms can be extrapolated 
to clinical isolates from geographical zones with 
a high incidence of primary antimony resistance. 
To address this question, we have characterized 
both the VL and the PKDL isolates from India 
and report that diverse mechanisms of resistance 
are operative in these isolates. This work aims at 
characterizing possible biomarkers for 
monitoring antimonial resistant visceral 
leishmaniasis and post-kala-azar dermal 
leismaniasis in the field isolates. 
In the present study, we report the role of thiols 
and also assessed the role of ABC transporter 
(MRPA), ornithine decarboxylase (ODC) and γ-
glutamylcysteine synthetase (γ-GCS) genes as 
potential biomarkers for monitoring antimonial 
resistance in Indian leishmaniasis.  
Materials and Methods 
Parasite and culture conditions 
Promastigotes of Leishmania donovani clones, 
AG83 (MHOM/IN/80/AG83), 2001, MC4, MC7, 
MC8 and  MC9 were isolated from patients with 
VL and strains, RK1, MS2, NR3A, RMP8 
(HM/IN/RMP-8), RMP-19 (HM/IN/RMP-19), 
RMP142 (HM/IN/RMP-142), RMP155 
(HM/IN/RMP-155) and  RMP240 
(HM/IN/RMP-240) used in the present study 
were isolated from patients with PKDL [19]. 
Clinical isolates obtained from VL and PKDL 
patients who responded to SAG chemotherapy 
were designated as SAG-S (SAG-sensitive) 
whereas isolates from VL and PKDL patients 
who did not respond to SAG were designated as 
SAG-R (SAG-resistant). SAG-sensitive strains, 
AG83-S, 2001-S, MC7-S, RK1-S, MS2-S and the 
nine SAG-R isolates, MC4-R MC8-R, MC9-R, 
NR3A-R, RMP8-R, RMP19-R, RMP142-R, 
RMP155-R and RMP240-R have been 
characterized earlier [20].  Clinical history of the 
patient infected with the strain RK1-S showed 
that the interval between the cure of VL and the 
onset of PKDL was 2.5 years where as in the case 
of PKDL patients infected with the strains, MS2-
S and NR3A-R, the interval between the cure of 
VL and the onset of PKDL was 7 and 11 years 
respectively. The interval between the cure of VL 
and the onset of PKDL for the remaining isolates 
is not known. The clinical isolates were 
maintained in vitro in the absence of the drug 
pressure. Promastigotes were routinely cultured 
at 220C in modified M-199 medium (Sigma, 
USA) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS; Gibco/BRL, Life 
Technologies Scotland, UK) and 0.13 mg/mL 
penicillin and streptomycin. This study has the 
approval of the Institutional level ethics 
committee.  
DNA and RNA manipulations 
Chromosomes of the clinical isolates were 
separated by pulse field gel electrophoresis 
(PFGE) in which low melting agarose blocks, 
containing embedded cells (108/ml log phase 
promastigotes) were electrophoresed in a 
contour clamped homogeneous electric field 
apparatus (CHEF DRIII, Bio-Rad) as reported 
earlier [20]. Mid log phase promastigotes (~2 x 
109 cells) of all the field isolates were used for 
isolation of genomic DNA. 5 µg of genomic 
DNA was digested with HindIII enzyme and 
subjected to electrophoresis. Total RNA was 
isolated from promastigotes (2 x 108 cells) using 
RNAeasy Plus Mini Kit (Qiagen). Standard 
protocols were followed for Southern 
hybridization [21]. DNA probes used in the 
present study included a 400-bp MRPA 
fragment (released from plasmid PM12 that was 
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digested with BamHI and PstI), a 2.3-kb γGCS 
fragment - (derived from plasmid pspαhygroα-
γGCS digested with HindIII and XbaI), a 2.0-kb 
ODC-full length probe (derived from plasmid 
pspαhygroα-ODC digested with HindIII and 
XbaI) and a 1.6-kb 5’-PTR1 probe derived from 
plasmid (psp72-Y-hygro-5’-PTR1). 
cDNA synthesis and real time RT- PCR  
Total RNA was isolated from 108 Leishmania cells 
in the mid-log phase of growth using the 
RNeasy Plus Mini Kit (Qiagen) as described by 
the manufacturer. Quality and quantity of the 
RNA were determined using the RNA 6000 
Nano Lab chip kit on the Bio-analyzer 2100 
(Agilent Technologies). The sequences of the 
primers for MRPA are forward 5’-
GCGCAGCCGTTTGTGCTTGTGG-3’ and 
reverse 5’-TTGCCGTACGTCGCGATGGTGC-3’ 
and for the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) control forward 5’-
GAAGTACACGGTGGAGGCTG and reverse 5’-
CGCTGATCACGACCTTCTTC primers. The 
sequences of the primers for ODC are forward 
5’- GATGGTGCGCCCTTACTTTGC-3’and 
reverse 5’-TTCCATCTCCAGCGGGTTGTCC-3’, 
and for the γGCS, forward 5’-
CATTGGCTGGCGCGTTGAGTTC-3’ and 
reverse 5’-ATGTGCGCGGCCCATATTCTCG -3’ 
primer.  Complementary DNAs from 
promastigotes were synthesized from 500 ng of 
total RNA using the AccuSuperscript High 
Fidelity RT-PCR kit (Stratagene, La Jolla) and 
Oligo (dT)18 primers following manufacturer’s 
instructions. Real-time PCR was performed in 
triplicate in 25 l volumes using QuantiFast 
SYBR Green PCR Master Mix (Qiagen) in an 
Applied Biosystem 7500. Reactions were run 
using the following thermal profile: initial 
denaturation at 95°C for 5 min followed by 40 
cycles with denaturation at 95°C for 30 s, 
annealing at 62°C for 1 min and extension at 
72°C for 20 s. The PCR was followed by a melt 
curve analysis to ascertain that the expected 
products were amplified. The relative amount of 
PCR products generated from each primer set 
was determined based on the threshold cycle 
(Ct) value and amplification efficiencies and was 
normalized by dividing the values by the 
relative amount of the GAPDH gene used as a 
control. 
Transfection and overexpression of the MRPA 
and γ-GCS gene 
Episomal Leishmania expression vectors, pGL-
NEOLUC containing luciferase encoding 
DNA and neomycin phosphotransferase 
selectable marker, psphygro-GCS containing 
coding sequence for heavy subunit of GCS with 
hygromycin phosphotransferase as selectable 
marker and pGEM72f-neo-MRPA containing 
MRPA coding DNA and neomycin 
phosphotransferase as selectable marker were 
obtained as gifts from Prof. Marc Ouellette, 
Centre de Recherche en Infectiologie du Centre 
de Recherche du CHUL, Universite Laval, 
Quebec, Canada. Twenty µg of each construct 
was transfected into L. donovani promastigotes 
by electroporation. Electroporation was done 
with a single pulse with the following 
parameters 450 V, 500 F (Bio-Rad). 
Transfectants were selected for resistance to 
either G418 (40 μg/ml) or hygromycin B (80 
μg/ml) as described earlier [22]. 
Chemosensitivity profiles of SAG-S and SAG-R 
strains in an amastigote macrophage model 
Stationary phase Leishmania promastigotes 
expressing the luciferase gene (pGL-
NEOLUC) and psphygro-GCS containing 
coding sequence for heavy subunit of GCS with 
hygromycin phosphotransferase as selectable 
marker or pGEM72f-neo-MRPA containing 
MRPA coding DNA and neomycin 
phosphotransferase as selectable marker were 
infected into J774A.1 macrophages. Macrophage 
cell line J774A.1 (American Type Culture 
Collection) was maintained at 37C in RPMI-
1640 medium (Sigma) containing 10% heat 
inactivated fetal bovine serum. Briefly, J774A.1 
murine macrophages (1 x 105 cells/ petridish) 
were infected with 1 x 106 promastigotes 
(expressing the luciferase gene (pGL-
NEOLUC) in M199 media with 10% FBS. 
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After 3 h, the non-internalized parasites were 
washed off and SAG was added at different 
concentrations (10 – 100 g/ml). After 5 days of 
drug exposure, plates containing adherent 
macrophages were washed and luciferase 
activity was determined [22]. The 50% inhibitory 
concentration (IC50) was determined from the 
graph representing different concentrations of 
SAG plotted against relative light units (RLU) 
produced by luciferase expressing parasites.  
Thiol analysis 
Thiols were derivatized with 
monobromobimane and separated by high-
perfomance liquid chromatography (HPLC) as 
reported earlier [18].  
Statistical analysis  
Data was analyzed by the Student’s t- test. The 
data is represented as mean ± S.D. The results 
are representative of three independent 
experiments. A p value of < 0.05 was considered 
statistically significant. 
Results 
Intracellular thiol levels in SAG-S and SAG-R 
clinical isolates 
Resistance to antimonials in clinical isolates is 
not well defined. Understanding the mechanism 
of resistance to antimony in clinical isolates of L. 
donovani will aid in the development of 
biomarkers for antimony resistance and this in 
turn will enable the clinicians to monitor the 
treatment of the patients. With this background 
in mind, we used the previously characterized 
SAG-S and SAG-R, VL and PKDL clinical 
isolates for the present study [20]. 
A total of fourteen field isolates were used to 
assess the putative role of the ABC transporter 
MRPA, ornithine decarboxylase and γ-
glutamylcysteine synthetase in antimony -
susceptible and -resistant clinical isolates of L. 
donovani from India. As reported earlier, SAG-S 
isolates, AG83-S, 2001-S, MC7-S, RK1-S and 
MS2-S coming from SAG responsive patients 
had IC50 values 6.2 ± 1.8, 0.9 ± 0.12,  8 ± 3.3, 0.01 ± 
0.02 and 4.75 ± 0.12 µM respectively whereas the 
SAG-R isolates, MC4-R, MC8-R, MC9-R, NR3A-
R, RMP8-R, RMP19-R, RMP142-R, RMP155-R, 
RMP240-R coming from the SAG-unresponsive 
patients had IC50s that were 2 to >10 fold higher 
than that of the sensitive isolate, AG83-S.(20) 
RK1-S was the most sensitive of all the isolates 
with an IC50   of 0.01 ± 0.02 µM. 
 Intracellular thiol levels were quantified in the 
SAG-S and SAG-R isolates (Figure 1). SAG-R 
isolates maintained significantly higher levels of 
cysteine and glutathione as compared to the  
SAG-S isolates. Cysteine levels in the SAG 
resistant strains MC4-R, MC8-R, MC9-R, NR3A-
R, RMP8-R, RMP19-R, RMP142-R, RMP155-R 
and RMP240-R were  ~1.7, ~1.6, ~1.5, ~2.7, ~2.0, 
~1.8, ~1.8,  ~2.0 and ~1.7 -fold higher 
respectively when compared to the SAG-S 
isolate, 2001-S (Figure 1A). 
Similarly GSH levels showed significant increase 
in the SAG-R isolates, MC4-R (~2.7-fold), MC8-R  
(~3.6 -fold), MC9-R (~3.0 -fold), NR3A-R (~2.0 -
fold), RMP8-R (~3.2 -fold), RMP19-R (~2.5 -fold), 
RMP142-R (~3.1 -fold), RMP155-R (~2.4 -fold) 
and RMP240-R (~3.0 -fold) when compared to 
the SAG sensitive isolate, 2001-S (Figure 1B). A 
SAG-S strain, RK1-S had glutathione levels that 
were ~2.1 -fold higher when compared to the 
SAG sensitive isolate, 2001-S.  Interestingly, no 
significant difference was observed in the 
trypanothione levels between the SAG-S and 
SAG-R isolates (Figure 1C). Similar observation 
was made in our earlier study using a small set 
of clinical isolates [23].  
Gene copy number and expression profiling of 
the ABC transporter MRPA in SAG-S and SAG-R 
clinical isolates 
Our earlier work on the clinical kala azar L. 
donovani isolates from India showed MRPA 
overexpression as an important SAG resistance 
factor [23]. To further validate, the role of MRPA 
gene in antimony resistance phenotype, we 
checked the amplification of MRPA gene by 
Southern blot hybridization. Southern blot 
hybridization of total genomic DNA digested 
with HindIII followed by hybridization with 
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Figure 1: Intracellular levels of thiols, cysteine, 
glutathione and trypanothione in SAG-S and SAG-R 
L. donovani VL and PKDL clinical isolates.  A: Cysteine 
levels B: Glutathione levels C: Trypanothione levels. 
Thiols were derivatized with monobromobimane and 
separated by high-perfomance liquid chromatography 
(HPLC). Each value is the mean  SD of triplicates 
from two independent experiments.  a indicates p 
<0.01; b indicates p < 0.001; c indicates p < 0.0004 
when compared to 2001-S respectively 
MRPA specific probe was done. SAG-sensitive 
and SAG-resistant field isolates showed a single 
hybridizing fragment of 11-kb indicating that 
MRPA gene exist as a single copy gene in all the 
isolates (Figure 2A). Quantitation of the 
Southern blot hybridization signal was done 
using ImageQuant 5.2 (Molecular Dynamics) 
and the fold difference in DNA copy number of 
the isolates with the AG83-S or 2001-S was 
calculated. Amplification of MRPA gene was 
observed in the resistant isolates, MC4-R, MC8-
R, MC9-R, RMP19-R, RMP142-R, RMP155-R and 
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Figure 2: A: Southern blot analysis of MRPA and PTR1 
genes in SAG-S and SAG-R L. donovani VL and PKDL 
clinical isolates. Total genomic DNA of isolates were 
digested with HindIII, electrophoresed, blotted and 
hybridized with a MRPA specific probe of 400-bp and 
6 kb 5’-PTR1 specific probe. The size of the 
hybridizing bands was determined using HindIII  
 
 
 digested lambda DNA. The blot was rehybridized 
with α-tubulin probe to monitor the amount of 
digested DNA layered on the gel. Quantitation of 
Southern blot was done by Image-quant software 5.2 
(Molecular dynamics) and the fold difference in DNA 
copy number of MRPA is presented below each blot. 
B: Southern blot analysis of the pulse field gel 
electrophoresis of SAG-sensitive (SAG-S) and SAG-
resistant (SAG-R) isolates of Leishmania donovani 
chromosomes. Agarose blocks containing 
chromosomal DNAs of promatigotes of L. donovani 
clinical isolates were prepared and subjected to pulsed 
field gel electrophoresis for 24 hours run time and 
hybridized with a MRPA specific probe of 400-bp. C: 
Real time RT-PCR expression analysis of MRPA gene 
in L. donovani clinical isolates. MRPA RNA expression 
ratios in promastigotes of SAG -resistant isolates are 
relative to the SAG-sensitive isolate (2001-S). The 
graph represents mean of three independent 
experiments performed from three different RNA 
preparations. 
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Figure 3: A: Characterization of ODC gene in SAG-S and SAG-R isolates L. donovani VL and PKDL clinical isolates. 
Genomic DNAs were isolated and digested with HindIII and hybridized with a full-length ODC specific probe, 
derived from the L. donovani ODC gene. The sizes of the hybridizing bands were determined using HindIII digested 
lambda DNA marker. The blot was rehybridized with α-tubulin probe to monitor the amount of digested DNA 
layered on the gel. B: Real time RT-PCR expression analysis of ODC in L. donovani clinical isolates. ODC RNA 
expression ratios in the SAG- resistant isolates are relative to the SAG-sensitive isolate, 2001-S. Results are mean of 
three independent experiments performed from three different RNA preparations.  
RMP240-R (Figure 2A). No amplification was 
observed in the resistant isolates, NR3A-R and 
RMP8-R (Figure 2A). The amplification observed 
in the resistant isolates was further analyzed by 
PFGE (Figure 2B). None of the resistant isolates 
showed circular amplification as was observed 
in our earlier studies with limited number of 
isolates [23]. Interestingly, two sensitive PKDL 
isolates, RK1-S and MS2-S and one resistant 
PKDL isolate, NR3A-R had the presence of 
MRPA on two chromosomes as indicated by 
their characteristic migration in PFGE (Figure 
2B). We had earlier reported co-amplification of 
pterin reductase gene (PTR1) with MRPA in the 
clinical isolates [23]. In the present study, co-
amplification of PTR1 gene with MRPA gene 
was not observed in any of the clinical isolates as  
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Figure 4: A: Southern blot analysis of the -GCS gene in the SAG-sensitive and the SAG-resistant Leishmania donovani 
VL and PKDL field isolates. Total genomic DNA was isolated and digested with HindIII. The digested DNA was 
electrophoresed, blotted and hybridized with -GCS probe. The sizes of the hybridizing bands were determined using 
HindIII digested λ- DNA. The blot was rehybridized with α-tubulin probe to monitor the amount of digested DNA 
layered on the gel. B: Real time RT-PCR expression analysis of -GCS gene in L. donovani clinical isolates.  -GCS gene 
expression ratios in the SAG-resistant isolates are relative to the SAG- sensitive isolate, 2001-S. Results are mean of 
three independent experiments performed from three different RNA preparations.
determined by Southern-blot analysis using 
PTR1-specific probe (Figure 2A). 
Comparison of MRPA gene expression in SAG-S 
versus SAG-R field isolates was done to verify if 
there is any correlation between MRPA gene 
expression and SAG susceptibility profile of the 
clinical isolates. Total RNA from promastigotes 
of the clinical isolates was isolated and 
complementary DNAs were synthesized. Real-
time -PCR using QuantiFast SYBR Green PCR 
Master Mix (Qiagen) with MRPA (gene specific) 
and GAPDH (internal control) primers was  
performed. Up-regulation of MRPA expression 
was observed in the resistant clinical isolates. 
MRPA expression in the resistant strains, MC4-
R, MC8-R, MC9-R, NR3A-R, RMP8-R, RMP19-R, 
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RMP142-R, RMP155-R and RMP240-R was ~4-, 
~4.2-, ~9.6-, ~7.2-, ~6.1-, ~6.8-, ~6.0-, ~7.5-  and 
~4.4- fold more respectively when compared to 
the expression in the sensitive isolate, 2001-S  
(Figure 2C).  
Gene copy number and expression profiling of 
the ornithine decarboxylase (ODC) gene in 
SAG-S and SAG-R clinical isolates. 
Ornithine decarboxylase (ODC) is the rate-
limiting enzyme of the polyamine biosynthetic 
pathway. In addition to MRPA, overexpression 
of the ODC gene has been reported in the 
antimony resistant mutants [23-25]. These 
observations prompted us to determine if 
amplification of the ODC gene occured in our  
clinical isolates. Southern-blot analysis of the 
total genomic DNA digested with HindIII and 
hybridized with the ODC specific probe was 
done. SAG-S and SAG-R isolates showed a 
single copy of the ODC gene (Figure 3A) with 
the exception of three PKDL isolates, RK1-S, 
MS2-S and NR3A-R. Interestingly, two copies of 
the ODC gene were observed in these three 
PKDL isolates (Figure 3A). 
Comparison of ODC gene expression in SAG-S 
versus SAG-R field isolates was done to verify if 
there is any correlation between the gene 
 expression and SAG susceptibility profile of the 
clinical isolates. Real-time PCR with the ODC 
(gene specific) and the GAPDH (internal control) 
primers was performed. Up-regulation of the 
ODC expression was observed in the resistant 
clinical isolates. ODC expression in the resistant 
strains, MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-
R, RMP19-R, RMP142-R, RMP155-R and 
RMP240-R was ~3.6-, ~7.4-, ~3.1-, ~2.7-, ~2.3-, 
~3.3-, ~3.5-, ~2.8-  and ~3.0- fold more 
respectively when compared to the sensitive 
isolate, 2001-S  (Figure 3B). SAG-S isolate, RK1-S 
was an exception since it was the only sensitive 
isolate that showed 2.9-fold up-regulation when 
compared to the reference strain, 2001-S and also 
in comparison with all other SAG-S isolates 
(Figure 3B). No uniform correlation was 
observed between gene amplification and ODC 
gene expression in these isolates. 
Gene copy number and expression profiling of 
the γ-glutamylcysteine synthetase (γ-GCS) gene 
in SAG-S and SAG-R clinical isolates  
In addition to MRPA and ODC, another locus 
that has been reported to be amplified in the 
antimony-resistant isolates is the GSH1 gene 
coding for the heavy subunit of -GCS. -GCS is 
the rate limiting enzyme for GSH synthesis 
[14,23]. We performed Southern blot analysis of 
the total genomic DNA digested with HindIII 
and hybridized with the -GCS specific probe. 
Southern blot analysis of the -GCS gene showed 
two copies in a resistant isolate MC4-R but in all 
other isolates, -GCS probe hybridized to a single 
hybridizing fragment  of 10-kb (Figure 4A). 
SAG-S isolate, RK1-S was again an exception 
since it showed amplification of the -GCS gene 
(Figure 4A). 
Comparison of GCS gene expression in SAG-S 
versus SAG-R field isolates was done to verify if 
there is any correlation between gene expression 
and SAG sensitivity profile of the clinical 
isolates. Real-time PCR using -GCS (gene 
specific) and GAPDH (internal control) primers 
was performed. Up-regulation of -GCS 
expression was observed in the resistant clinical 
isolates. -GCS expression in the resistant strains, 
MC4-R, MC8-R, MC9-R, NR3A-R, RMP8-R, 
RMP19-R, RMP142-R, RMP155-R and RMP240-R 
was 4.3-, 5.2-, 6.4-, 5.5-, 3.0-, 5.0-,  5.3-, 4.2-  and 
8.8- fold more respectively compared to the 
expression in the sensitive isolate, 2001-S  
(Figure 4B). In the present study though up-
regulation of -GCS was observed in all SAG-R 
isolates, interestingly one SAG-S isolate, RK1-S 
showed 5.5-fold up-regulation of GCS 
expression when compared to a SAG-S isolate, 
2001-S (Figure 4B). L-butathione-sulfoxamine 
(BSO), an inhibitor of -GCS was used to 
compare its effect on the SAG-S isolate, RK1-S 
and 2001-S. RK1-S promastigotes over-
expressing -GCS were ~5 fold more resistant to 
BSO when compared to the IC50  of 
promastigotes of the 2001-S, the IC50 being 6.5 ± 
0.5 mM and 1.3 ± 0.3 mM respectively. 
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Figure 5: Over-expression of MRPA and γ-GCS gene 
in a sensitive L. donovani isolate. A: Transfection of 
MRPA in SAG-sensitive isolate leads to resistance to 
antimony in amastigotes. AG83-S (-■-) was transfected 
with pGL-NEOLUC, AG83-S + LdMRPA (-□-) was 
transfected with pGEM72f-neo-MRPA + pGL-
NEOLUC and sensitivity to SAG in the J774A.1 line 
was measured as described in Materials and methods. 
Each data point represents the mean  SD of three 
determinations. Northern blot analysis (insets in A) of 
vector transfected controls and MRPA transfected 
lines was performed as described under methods 
section B: Transfection of γ-GCS gene in SAG-
sensitive isolate leads to antimony resistance in 
intracellular amastigotes. AG83-S (-■-) transfected 
with pGL-NEOLUC, AG83-S + γ-GCS (-□-) 
transfected with psphygro-GCS + pGL-
NEOLUC and sensitivity to SAG measured as 
described in Materials and methods. Each data point 
represents the mean  SD of three determinations. 
Northern blot analysis (insets in B) of vector 
transfected controls and γ-GCS transfected lines was 
performed as described under methods section.  
Overexpression of MRPA or -GCS in an 
antimony-sensitive isolate conferred increased 
expression and resistance to antimony  
To determine whether overexpression of MRPA 
and -GCS conferred antimony resistance in a 
sensitive isolate, we transfected MRPA or -GCS 
constructs into a SAG-S isolate, AG83-S. These 
MRPA and -GCS recombinant parasites were 
co-transfected with pGL-NEOLUC, encoding 
LUC. Intracellular amastigotes over-expressing 
MRPA (IC50, 32.3 ± 6.4 g/ml) were 3.6-fold 
more resistant to SAG when compared to 
amastigotes of the parent strain transfected with 
the control vector (IC50, 9 ± 0.5 g/ml) (Figure 
5A).  Intracellular amastigotes over-expressing -
GCS were 3.3-fold resistant to SAG when 
compared to the sensitive L. donovani the IC50 
value being (29.7 ± 1.5 g/ml) respectively 
(Figure 5B). In our previous studies we had 
demonstrated that the ODC overexpressors 
exhibited significant resistance to Pentostam 
compared to the wild type cells (26). Intracellular 
amastigotes over-expressing ODC (IC50, > 80 
g/ml) were >8.8-fold more resistant to SAG 
when compared to amastigotes of the parent 
strain transfected with the control vector [26].  
Discussion 
Currently, chemotherapy is the only effective 
way to control Leishmania infection. Pentavalent 
antimonials are the mainstay of therapy in the 
treatment of visceral leishmaniasis [27].  Increase 
in resistance to SAG has led to an upsurge in 
therapeutic failure and in the absence of limited 
chemotherapeutic alternatives, it is extremely 
necessary to identify biomarkers for monitoring 
antimony resistance.  
 Trivalent form of the antimonial drug (SbIII) is 
the prodrug that is formed by conversion of 
pentavalent antimony (SbV) by a putative 
metalloid reductase present in the macrophages 
[28]. Antimonial resistance in both laboratory 
mutants and clinical isolates has been associated 
with (a) decreased uptake of the drug through 
aquaglyceroporin (AQP1) that codes for the 
protein responsible for SbIII transport 
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[11,12,20,29] (b) Over expression of ODC and γ-
GCS enzymes of the trypanothione biosynthetic 
pathway [2,25] and (c) increased expression of 
the ABC transporter MRPA, which sequesters 
SbIII-thiol conjugate [16,23]. 
We had earlier reported decreased uptake of 
antimony in all nine SAG-R isolates used in the 
present study. Down-regulation of SbIII influx 
pump; aquaglyceroporin (AQP1) was observed 
in seven out of the nine resistant isolates  Strains, 
MC8-R and NR3A-R were an exception since 
they showed up-regulation of  AQP1 gene 
expression [20]. 
The ABC transporter gene MRPA causes drug 
sequestration in Leishmania promastigotes and 
amastigotes selected for SbIII resistance [17,30]. 
Increased copy number of MRPA has been 
reported in SbIII resistant mutant [2]. Our earlier 
studies using limited number of SAG-S and 
SAG-R clinical isolates showed amplification of 
MRPA gene as part of an extrachromosomal 
circle [23]. In the present study, we found 
distinct correlation between copy number of 
MRPA gene and antimony sensitivity in a 
majority of the isolates (Figure 2A). However, 
two SAG-R strains, NR3A-R and RMP8-R were 
an exception. We have reported earlier that ABC 
transporter gene MRPA was amplified in three 
out of four resistant VL isolates as part of the 
extrachromosmal circle and coamplifcation of 
PTR1 along with MRPA suggested amplification 
of the H locus in SAG-resistant clinical isolates 
[23]. In the present study, co-amplification of 
PTR1 gene with MRPA gene was not observed in 
any of the clinical isolates. CHEF gel analysis of 
the SAG-S and SAG-R isolates did not show any 
circular amplification in any of the SAG-R 
isolates. MRPA gene expression in SAG-S versus 
SAG-R field isolates showed correlation between 
MRPA gene expression and SAG susceptibility 
profile of the clinical isolates. The present 
observation validated our earlier results where 
we have shown correlation between MRPA gene 
expressions with the antimony resistant clinical 
profile in the field conditions [23].  
In our previous study amplification of ODC gene 
was noted in the resistant isolates but not that of 
the γ-GCS [23]. In another study on L. donovani 
isolates from Nepal, expression of γ-GCS and 
ODC was significantly decreased in the resistant 
isolates [31]. In the present study we observed 
increased expression of ODC gene and γ-GCS in 
all SAG-R isolates.  
It has been reported earlier that ABC transporter 
MRPA, confers resistance to antimonials by 
sequestration of metal thiol conjugates in an 
intracellular organelle located close to the 
flagellar pocket [16]. This model has been 
demonstrated in promastigotes of L. tarentolae, in 
amastigotes and also in clinical isolates from 
India [16,23,30]. These observations clearly 
highlighted the importance of intracellular thiol 
in MRPA mediated efflux of the antimony.  An 
increase in cysteine and glutathione levels were 
reported in antimony resistant L. donovani 
clinical isolates [23]. In the present study also, 
we observed increase in cysteine and glutathione 
levels in all SAG-R isolates. However, no change 
in trypanothione levels were observed in SAG-R 
isolates in comparison to SAG-S isolates. Similar 
observation was made in our analysis of the 
mode of action of antimony in clinical isolates 
and earlier studies in L. infantum resistant to 
Sb(III) [23]. It was pointed out that antimony 
possibly depleted trypanothione by efflux of Sb-
trypanothione conjugate [16]. It is possible that 
the efflux system is increased in the resistant 
isolates thereby leading to increased 
trypanothione efflux. This would explain the 
constant levels of trypanothione in the present 
study in the resistant isolates.  
RK1-S though a SAG-S isolate, was an exception 
to the mutlifactorial antimony resistant 
mechanisms reported in clinical isolates and also 
in the lab based resistant isolates. Clinical history 
of the RK1-S patient showed that the interval 
between the cure of VL and the onset of PKDL 
was 2.5 years where as MS2-S and NR3A-R, 
PKDL isolates the interval between the cure of 
VL and the onset of PKDL was 7 and 11 years 
respectively. It will be interesting to look at the 
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PKDL isolates with known clinical history in 
order to determine if this interval has a role to 
play in antimony susceptibility/resistance. 
The data presented here in VL and for the first 
time in PKDL isolates, establishes the relevance 
of overexpression of γ–GCS and ODC and an 
increased expression of MRPA that may be 
responsible for an increased efflux of thiol-Sb-III 
conjugate. Our data further confirms that 
resistance mechanisms present in the laboratory 
strains can be found in the clinical isolates.  
Further work is presently going on the 
laboratory to get a global overview of the 
resistant mechanism by proteomics approach in 
order to find other possible resistant 
determinants. It will further help in proper 
selection of therapeutic regimen and improve 
treatment strategy against leishmaniasis. 
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